Hypothesis

Aged skeletal muscle loses eosinophils not because of deficient IL‑5 production but because resident eosinophils fail to sustain an autocrine IL‑33 loop that normally maintains their survival and IL‑4‑secreting capacity. Restoring this IL‑33→IL‑5 axis within muscle will rescue eosinophil numbers, improve regeneration, and attenuate age‑related fibrosis.

Background

• Eosinophils support muscle repair by secreting IL‑4, which expands fibro/adipogenic progenitors (FAPs) while blocking adipogenic differentiation [1].
• IL‑5 drives eosinophil differentiation, survival, and tissue homing, but IL‑33 acts upstream, expanding IL‑5Rα⁺ precursors and inducing systemic IL‑5 [3].
• With age, eosinophils decline in visceral adipose tissue, correlating with elevated CCL11/CCL2 and systemic inflammation [4]; young eosinophil transfer reverses these effects in an IL‑4‑dependent manner.
• Direct eosinophil‑satellite cell interactions in muscle remain poorly defined, raising the possibility that eosinophil‑derived factors beyond IL‑4 influence myogenesis.

Mechanistic insight

We propose that, in addition to the circulating IL‑33→IL‑5 axis, muscle‑resident eosinophils produce IL‑33 in response to damage‑associated molecular patterns (DAMPs) released during injury. This locally secreted IL‑33 engages the IL‑33 receptor (ST2) on eosinophils themselves, activating NF‑κB and upregulating Bcl‑XL, thereby providing an IL‑5‑independent survival signal. Simultaneously, IL‑33 signaling enhances IL‑4 transcription via GATA‑3 activation, amplifying the pro‑regenerative cytokine milieu. In aged muscle, accumulated senescent cells and extracellular matrix stiffness dampen DAMP release, reducing eosinophil‑derived IL‑33 and breaking this autocrine loop, leading to eosinophil attrition despite normal systemic IL‑5 levels.

Testable predictions

1. Prediction 1 – Injured young muscle will show a transient increase in eosinophil intracellular IL‑33 protein and phospho‑p65 (NF‑κB) within 6 h post‑injury; aged muscle will exhibit blunted IL‑33 induction.
2. Prediction 2 – Genetic deletion of Il33 specifically in eosinophils (using Epx‑Cre Il33^fl/fl) will impair muscle regeneration, increase fibrosis, and reduce IL‑4+ eosinophil numbers after cardiotoxin injury, without affecting blood eosinophil counts.
3. Prediction 3 – Exogenous administration of recombinant IL‑33 (or an ST2 agonist) to aged injured muscle will restore eosinophil survival (Bcl‑XL upregulation), elevate local IL‑4, improve satellite cell activation, and decrease collagen deposition.
4. Prediction 4 – Blocking IL‑5 with anti‑IL‑5 antibody will not abolish the regenerative benefit of IL‑33 treatment in aged muscle, confirming IL‑5 independence of the pathway.

Experimental approach

• Model: Cardiotoxin (CTX) injury in tibialis anterior of young (3 mo) and aged (22 mo) mice.
• Readouts: Flow cytometry for eosinophil viability (Annexin V/7‑AAD), intracellular IL‑33, phospho‑p65, and IL‑4; immunohistochemistry for eosinophil infiltration, central nucleation, fibrosis (Sirius Red), and Pax7⁺ satellite cells; functional assay (in‑situ tetanic force).
• Interventions: (a) Epx‑Cre Il33^fl/fl mice; (b) local injection of rIL‑33 or ST2 agonist; (c) systemic anti‑IL‑5 (clone TRFK5) as control.
• Analysis: Two‑way ANOVA with age and treatment as factors; post‑hoc Tukey test.

Potential pitfalls and alternatives

• Compensatory cytokines (IL‑3, GM‑CSF) may sustain eosinophil survival; we will measure Bcl‑XL levels after IL‑33 neutralization to assess dependence.
• IL‑33 can act on other stromal cells; using eosinophil‑specific Il33 knockout isolates the eosinophil‑derived source.
• If IL‑33 fails to rescue eosinophils, we will test whether exogenous IL‑4 alone can bypass the need for eosinophil survival, distinguishing survival versus effector functions.

Significance

Demonstrating an eosinophil‑intrinsic IL‑33 survival niche would reveal a novel, tissue‑autonomous mechanism that sustains reparative eosinophils independent of circulating IL‑5. This insight could guide therapies that boost local IL‑33 signaling to rejuvenate aged muscle, improve regeneration, and mitigate fibrosis without broadly elevating eosinophil numbers systemically.